A citation-based method for searching scientific literature

Hung-Yi Chen, Jing-Yang Huang, Wun-Zhih Siao, Gwo-Ping Jong. Cardiovasc Diabetol 2020
Times Cited: 5







List of co-cited articles
22 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
707
60

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
132
60

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
60

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Nikole J Byrne, Nobutoshi Matsumura, Zaid H Maayah, Mourad Ferdaoussi, Shingo Takahara, Ahmed M Darwesh, Jody L Levasseur, James Won Suk Jahng, Dyonne Vos, Nirmal Parajuli,[...]. Circ Heart Fail 2020
22
40

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li,[...]. Cardiovasc Diabetol 2019
72
40

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
195
40

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
M V Karg, A Bosch, D Kannenkeril, K Striepe, C Ott, M P Schneider, F Boemke-Zelch, P Linz, A M Nagel, J Titze,[...]. Cardiovasc Diabetol 2018
54
40

Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.
Hao Zhou, Shuyi Wang, Pingjun Zhu, Shunying Hu, Yundai Chen, Jun Ren. Redox Biol 2018
158
40


Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients.
Laween Uthman, Antonius Baartscheer, Cees A Schumacher, Jan W T Fiolet, Marius C Kuschma, Markus W Hollmann, Ruben Coronel, Nina C Weber, Coert J Zuurbier. Front Physiol 2018
43
40

Mitochondrial Dysfunction Underlies Cardiomyocyte Remodeling in Experimental and Clinical Atrial Fibrillation.
Marit Wiersma, Denise M S van Marion, Rob C I Wüst, Riekelt H Houtkooper, Deli Zhang, Natasja M S de Groot, Robert H Henning, Bianca J J M Brundel. Cells 2019
17
40



Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
764
40

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Bowen Lin, Nobutaka Koibuchi, Yu Hasegawa, Daisuke Sueta, Kensuke Toyama, Ken Uekawa, MingJie Ma, Takashi Nakagawa, Hiroaki Kusaka, Shokei Kim-Mitsuyama. Cardiovasc Diabetol 2014
147
40

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
So Ra Kim, Sang-Guk Lee, Soo Hyun Kim, Jin Hee Kim, Eunhye Choi, Wonhee Cho, John Hoon Rim, Inhwa Hwang, Chan Joo Lee, Minyoung Lee,[...]. Nat Commun 2020
16
40

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
383
40

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
494
40

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
136
40

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur Heart J 2016
40

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
40


COVID-19 infection may cause ketosis and ketoacidosis.
Juyi Li, Xiufang Wang, Jian Chen, Xiuran Zuo, Hongmei Zhang, Aiping Deng. Diabetes Obes Metab 2020
101
20


Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
W Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J Davies. Metabolism 2018
60
20

Endothelial cell infection and endotheliitis in COVID-19.
Zsuzsanna Varga, Andreas J Flammer, Peter Steiger, Martina Haberecker, Rea Andermatt, Annelies S Zinkernagel, Mandeep R Mehra, Reto A Schuepbach, Frank Ruschitzka, Holger Moch. Lancet 2020
20

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).
Tao Guo, Yongzhen Fan, Ming Chen, Xiaoyan Wu, Lin Zhang, Tao He, Hairong Wang, Jing Wan, Xinghuan Wang, Zhibing Lu. JAMA Cardiol 2020
20

Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
Subodh Verma, Peter Jüni, C David Mazer. Lancet 2019
35
20


Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis.
Erkan Cure, Medine Cumhur Cure. Diabetes Metab Syndr 2020
26
20

Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury.
Sarayut Lahnwong, Siripong Palee, Nattayaporn Apaijai, Sirawit Sriwichaiin, Sasiwan Kerdphoo, Thidarat Jaiwongkam, Siriporn C Chattipakorn, Nipon Chattipakorn. Cardiovasc Diabetol 2020
6
20

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
Chaomin Wu, Xiaoyan Chen, Yanping Cai, Jia'an Xia, Xing Zhou, Sha Xu, Hanping Huang, Li Zhang, Xia Zhou, Chunling Du,[...]. JAMA Intern Med 2020
20

Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.
Antonio Ceriello, Eberhard Standl, Doina Catrinoiu, Baruch Itzhak, Nebojsa M Lalic, Dario Rahelic, Oliver Schnell, Jan Škrha, Paul Valensi. Diabetes Care 2020
30
20

Cardiovascular manifestations and treatment considerations in COVID-19.
Yu Kang, Tiffany Chen, David Mui, Victor Ferrari, Dinesh Jagasia, Marielle Scherrer-Crosbie, Yucheng Chen, Yuchi Han. Heart 2020
74
20


Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart.
Anne Van Steenbergen, Magali Balteau, Audrey Ginion, Laura Ferté, Sylvain Battault, Christophe de Meester de Ravenstein, Jean-Luc Balligand, Evangelos-Panagiotis Daskalopoulos, Patrick Gilon, Florin Despa,[...]. Sci Rep 2017
24
20

Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice.
Yohei Sawa, Maki Saito, Nanae Ishida, Miho Ibi, Naoko Matsushita, Yoshihiro Morino, Eiichi Taira, Masamichi Hirose. J Pharmacol Sci 2020
6
20

Late Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial Fibrillation.
Claire Poulet, Erich Wettwer, Morten Grunnet, Thomas Jespersen, Larissa Fabritz, Klaus Matschke, Michael Knaut, Ursula Ravens. PLoS One 2015
32
20

SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Piangkwan Sa-Nguanmoo, Pongpan Tanajak, Sasiwan Kerdphoo, Thidarat Jaiwongkam, Wasana Pratchayasakul, Nipon Chattipakorn, Siriporn C Chattipakorn. Toxicol Appl Pharmacol 2017
52
20

Critical role for calcium mobilization in activation of the NLRP3 inflammasome.
Tomohiko Murakami, Johan Ockinger, Jiujiu Yu, Vanessa Byles, Aisleen McColl, Aldebaran M Hofer, Tiffany Horng. Proc Natl Acad Sci U S A 2012
369
20

TNF-α induces Drp1-mediated mitochondrial fragmentation during inflammatory cardiomyocyte injury.
Yue-Liang Shen, Ying-Zhou Shi, Gai-Ge Chen, Lin-Lin Wang, Ming-Zhi Zheng, Hong-Feng Jin, Ying-Ying Chen. Int J Mol Med 2018
14
20

Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knockout mice.
Na Li, Tiannan Wang, Wei Wang, Michael J Cutler, Qiongling Wang, Niels Voigt, David S Rosenbaum, Dobromir Dobrev, Xander H T Wehrens. Circ Res 2012
96
20


Atrial metabolism and tissue perfusion as determinants of electrical and structural remodelling in atrial fibrillation.
Dragan Opacic, Kelly A van Bragt, Hussein M Nasrallah, Ulrich Schotten, Sander Verheule. Cardiovasc Res 2016
25
20

Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats.
Ting-I Lee, Yao-Chang Chen, Yung-Kuo Lin, Cheng-Chih Chung, Yen-Yu Lu, Yu-Hsun Kao, Yi-Jen Chen. Int J Mol Sci 2019
16
20

Inhibitors of the Na+/H+ exchanger cannot prevent atrial electrical remodeling in the goat.
Yuri Blaauw, Norbert Beier, Pepijn van der Voort, Arne van Hunnik, Ulrich Schotten, Maurits A Allessie. J Cardiovasc Electrophysiol 2004
8
20

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
Qingmiao Shao, Lei Meng, Sharen Lee, Gary Tse, Mengqi Gong, Zhiwei Zhang, Jichao Zhao, Yungang Zhao, Guangping Li, Tong Liu. Cardiovasc Diabetol 2019
22
20

Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
Julian Mustroph, Olivia Wagemann, Charlotte M Lücht, Maximilian Trum, Karin P Hammer, Can Martin Sag, Simon Lebek, Daniel Tarnowski, Jörg Reinders, Filippo Perbellini,[...]. ESC Heart Fail 2018
43
20

Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation.
Yumei Ye, Xiaoming Jia, Mandeep Bajaj, Yochai Birnbaum. Cardiovasc Drugs Ther 2018
21
20

The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Takao Sato, Yoshifusa Aizawa, Sho Yuasa, Shohei Kishi, Koichi Fuse, Satoshi Fujita, Yoshio Ikeda, Hitoshi Kitazawa, Minoru Takahashi, Masahito Sato,[...]. Cardiovasc Diabetol 2018
73
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.